Since the tumor cells were programmed cell death ligand 1 (PD-L1) positive (tumor proportion score = 1%), the patient underwent 4 courses of pembrolizumab plus carboplatin plus nab-paclitaxel chemotherapy in accordance with treatment guidelines for stage 4 NSCLC (Fig. 2). The gene discussed is CD274; the disease is non-small cell lung carcinoma.